No pleotropic effects of linagliptin on atherosclerotic plaques: Case closed.
作者信息
Al-Mallah Mouaz H, Hyafil Fabien, Santulli Gaetano
机构信息
Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX, USA.
Department of Nuclear Medicine, Centre Hospitalier Universitaire Bichat, Assistance Publique - Hôpitaux de Paris, Inserm 1148, Université Paris Diderot, Paris, France.
出版信息
Atherosclerosis. 2020 Jul;305:61-63. doi: 10.1016/j.atherosclerosis.2020.05.009. Epub 2020 May 28.
Abstract
摘要
相似文献
1
No pleotropic effects of linagliptin on atherosclerotic plaques: Case closed.利格列汀对动脉粥样硬化斑块无多效性作用：结案。
Atherosclerosis. 2020 Jul;305:61-63. doi: 10.1016/j.atherosclerosis.2020.05.009. Epub 2020 May 28.
2
Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A F-fluorodeoxyglucose study of a mouse model of atherosclerosis and type 2 diabetes.二肽基肽酶 4 抑制对动脉粥样硬化炎症的影响：载脂蛋白 E 基因敲除小鼠伴 2 型糖尿病动脉粥样硬化模型的 F-氟脱氧葡萄糖研究。
Atherosclerosis. 2020 Jul;305:64-72. doi: 10.1016/j.atherosclerosis.2020.03.029. Epub 2020 Apr 10.
3
Effect of the dipeptidyl peptidase-4 inhibitor linagliptin on atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits: iMap-IVUS and pathological analysis.西格列汀对 Watanabe 遗传性高脂血症兔动脉粥样硬化病变的影响：iMap-IVUS 与病理学分析。
Heart Vessels. 2021 Jan;36(1):127-135. doi: 10.1007/s00380-020-01689-8. Epub 2020 Sep 10.
4
Effect of Linagliptin on Arterial F-Fluorodeoxyglucose Positron Emission Tomography Uptake: A Randomized Controlled Trial (RELEASE).利格列汀对动脉F-氟脱氧葡萄糖正电子发射断层扫描摄取的影响：一项随机对照试验（RELEASE）。
J Am Coll Cardiol. 2017 Feb 28;69(8):1097-1098. doi: 10.1016/j.jacc.2016.12.018.
5
Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions.利拉利汀通过抑制炎症介导的 DPP-4 表达增加动脉粥样硬化病变中的 M2 巨噬细胞。
Biochem Biophys Res Commun. 2020 Mar 26;524(1):8-15. doi: 10.1016/j.bbrc.2020.01.027. Epub 2020 Jan 19.
6
Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.血管二肽基肽酶-4抑制对Zucker糖尿病脂肪大鼠血管保护的意义
J Pharmacol Sci. 2014;125(4):386-93. doi: 10.1254/jphs.14052fp. Epub 2014 Jul 17.
7
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?二肽基肽酶-4 抑制剂与 2 型糖尿病的心血管和肾脏疾病：我们从 CARMELINA 试验中学到了什么？
Diab Vasc Dis Res. 2019 Jul;16(4):303-309. doi: 10.1177/1479164119842339. Epub 2019 Apr 24.
8
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.在男性 2 型糖尿病患者中多次口服利拉利汀（一种二肽基肽酶-4 抑制剂）的药代动力学、药效学和耐受性。
Diabetes Obes Metab. 2009 Aug;11(8):786-94. doi: 10.1111/j.1463-1326.2009.01046.x. Epub 2009 May 19.
9
Linagliptin safety profile: A systematic review.利格列汀的安全性概况：一项系统评价。
Prim Care Diabetes. 2018 Dec;12(6):477-490. doi: 10.1016/j.pcd.2018.04.006. Epub 2018 May 28.
10
Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.与二肽基肽酶-4（DPP-4）结合决定了利拉利汀（BI 1356）的处置--在 DPP-4 缺乏和野生型大鼠中的研究。
Biopharm Drug Dispos. 2009 Nov;30(8):422-36. doi: 10.1002/bdd.676.
引用本文的文献
1
miR-7 Regulates GLP-1-Mediated Insulin Release by Targeting β-Arrestin 1.miR-7 通过靶向β-arrestin 1 调节 GLP-1 介导的胰岛素释放。
Cells. 2020 Jul 6;9(7):1621. doi: 10.3390/cells9071621.
本文引用的文献
1
Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A F-fluorodeoxyglucose study of a mouse model of atherosclerosis and type 2 diabetes.二肽基肽酶 4 抑制对动脉粥样硬化炎症的影响：载脂蛋白 E 基因敲除小鼠伴 2 型糖尿病动脉粥样硬化模型的 F-氟脱氧葡萄糖研究。
Atherosclerosis. 2020 Jul;305:64-72. doi: 10.1016/j.atherosclerosis.2020.03.029. Epub 2020 Apr 10.
2
Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.西他列汀可减缓冠心病合并 2 型糖尿病患者冠状动脉粥样硬化的进展。
Atherosclerosis. 2020 May;300:10-18. doi: 10.1016/j.atherosclerosis.2020.03.015. Epub 2020 Mar 21.
3
Mortality attributable to diabetes in 20-79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9 edition.2019 年国际糖尿病联盟糖尿病地图集第 9 版估算：20-79 岁成年人归因于糖尿病的死亡率。
Diabetes Res Clin Pract. 2020 Apr;162:108086. doi: 10.1016/j.diabres.2020.108086. Epub 2020 Feb 15.
4
Nuclear Imaging: Focus on Vascular Probes.核医学影像：关注血管探针。
Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1369-1378. doi: 10.1161/ATVBAHA.119.312586. Epub 2019 May 23.
5
Editorial: Cardiovascular Disease and Diabetes.社论：心血管疾病与糖尿病
Front Endocrinol (Lausanne). 2019 May 16;10:314. doi: 10.3389/fendo.2019.00314. eCollection 2019.
6
Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.二肽基肽酶4（DPP-4）抑制剂与2型糖尿病（T2DM）患者的心血管结局：一项系统评价和荟萃分析。
BMC Pharmacol Toxicol. 2019 Mar 4;20(1):15. doi: 10.1186/s40360-019-0293-y.
7
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.利拉利汀对比安慰剂对伴有高心血管和肾脏风险的 2 型糖尿病成人患者主要心血管事件的影响：CARMELINA 随机临床试验。
JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.
8
Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.阿格列汀是一种二肽基肽酶-4抑制剂，可减少巨噬细胞浸润，并抑制高胆固醇喂养兔的主动脉和冠状动脉粥样硬化。
Metabolism. 2016 Jun;65(6):893-903. doi: 10.1016/j.metabol.2016.03.010. Epub 2016 Mar 18.
9
DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages.二肽基肽酶-4（DPP-4）抑制通过将单核细胞诱导为M2巨噬细胞来改善动脉粥样硬化。
Int J Cardiol. 2015 Nov 15;199:163-9. doi: 10.1016/j.ijcard.2015.07.044. Epub 2015 Jul 13.
10
Carotid FDG Uptake Improves Prediction of Future Cardiovascular Events in Asymptomatic Individuals.颈动脉 FDG 摄取可改善无症状个体未来心血管事件的预测。
JACC Cardiovasc Imaging. 2015 Aug;8(8):949-56. doi: 10.1016/j.jcmg.2015.06.002. Epub 2015 Jul 15.
Zotero 插件